Tonix Vaccine Candidate, TNX-1800, Selected by NIH/NIAID Project NextGen for Inclusion in Trials

 NIAID is conducting early phase clinical trials on select next generation COVID-19 vaccine candidates with the intent to identify promising vaccine candidates

TNX-1800, a live virus percutaneous vaccine candidate, is based on Tonix’s recombinant pox virus (RPV) platform

Phase 1 clinical trial of TNX-1800 expected to start in the second half of 2024

NIAID will cover the full cost of the clinical trial; Tonix will supply the vaccine candidate

https://www.globenewswire.com/news-release/2023/11/02/2772216/28908/en/Tonix-Pharmaceuticals-Vaccine-Candidate-TNX-1800-Selected-by-NIH-NIAID-Project-NextGen-for-Inclusion-in-Clinical-Trials.html